EyePoint Pharmaceuticals, Inc. — Director's Dealing 2009

Nov 20, 2009

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: pSivida Corp. (PSDV)
CIK: 0001314102
Period of Report: 2009-11-19

Reporting Person: Ashton Paul (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2009-11-19	Common Stock	A	27431	—	Acquired	457522	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2009-11-19	Employee Stock Option (right to buy)	$4.01	A	315000	Acquired	2019-11-19	Common Stock (315000)	Direct

Footnotes

F1: This award was granted in lieu of a cash payment for part of the reporting person's fiscal year 2009 short term incentive compensation.

F2: Includes 16,781 shares of Common Stock held by the trustee of the Dr. Ashton Children's Irrevocable Trust as to which Dr. Ashton disclaims beneficial ownership.

F3: The option becomes exercisable in four equal annual installments beginning on the first anniversary of the date of grant.